Bronchopulmonary disposition of IV cefepime/taniborbactam (2–0.5 g) administered over 2 h in healthy adult subjects

INTRODUCTION: Taniborbactam (formerly VNRX-5133) is an investigational β-lactamase inhibitor in clinical development in combination with cefepime for the treatment of MDR Gram-negative pathogens. OBJECTIVES: To assess the safety profile and pulmonary disposition of 2–0.5 g cefepime/taniborbactam adm...

Descripción completa

Detalles Bibliográficos
Autores principales: Asempa, Tomefa E, Kuti, Joseph L, Nascimento, Jeffrey C, Pope, Samuel J, Salerno, Edward L, Troy, Patrick J, Nicolau, David P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9978582/
https://www.ncbi.nlm.nih.gov/pubmed/36617636
http://dx.doi.org/10.1093/jac/dkac447

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9978582/
https://www.ncbi.nlm.nih.gov/pubmed/36617636
http://dx.doi.org/10.1093/jac/dkac447

Ejemplares similares